NASDAQ$HUMA
Humacyte Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Humacyte reported Q1 2026 revenue of $0.5M with a net loss of $17.6M and diluted loss per share of $0.09.
For the quarter ended March 31, 2026, Humacyte recognized revenue of $0.5 million from biologics license and collaboration activity versus $0.3 million a year ago. Net loss was $17.6 million compared with $20.1 million, with diluted loss per share of $0.09 versus $0.11. R&D expense was $10.8 million as the company advanced human acellular vessel commercialization and clinical programs.
- Revenue of $0.5M from early commercial and collaboration activity.
- Net loss improved to $17.6M; diluted EPS was a loss of $0.09.
- R&D expense of $10.8M on HAV and pipeline indications.
- Commercial rollout of bioengineered vessels remains in early stages.
- Cash supports manufacturing scale-up and clinical trials.
Headline financials
Revenue & EPS history
Humacyte · Revenue · Quarterly
$495K
Forward guidance
Humacyte does not issue quantitative annual guidance in the 10-Q and discusses hospital adoption of HAV, manufacturing capacity expansion, and vascular trauma and dialysis access indications.
Tailwinds
- Net loss and loss per share improved year over year.
- Early revenue recognition as commercial deployments begin.
Headwinds
- Minimal revenue relative to R&D and manufacturing costs.
- Hospital adoption pace and reimbursement remain uncertain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+5.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+37.0%
Q2 2023
Best reaction
-30.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +22.9% | -1.5% | +15.2% | |
| Q4 2025 | -15.1% | -25.1% | -33.0% | |
| Q3 2025 | -3.2% | -11.7% | +2.3% | |
| Q2 2025 | -30.1% | -24.2% | -40.3% | |
| Q1 2025 | +19.5% | +23.8% | +25.4% | |
| Q4 2024 | -2.5% | -27.4% | -28.4% | |
| Q3 2024 | +4.9% | +1.5% | -8.2% | |
| Q1 2024 | +21.2% | +43.1% | +60.8% | |
| Q4 2023 | -12.8% | -13.9% | +2.8% | |
| Q3 2023 | +7.3% | +9.1% | +27.9% | |
| Q2 2023 | +37.0% | +8.9% | +19.0% | |
| Q1 2023 | -6.1% | -2.5% | +1.1% | |
| Q4 2022 | +4.9% | -1.3% | +7.1% | |
| Q3 2022 | +2.2% | -5.4% | -4.5% | |
| Q2 2022 | +8.6% | +9.1% | +2.5% | |
| Q1 2022 | -9.5% | -12.7% | -18.8% | |
| Q4 2021 | +14.1% | +12.2% | +16.5% | |
| Q2 2021 | +14.1% | +12.2% | +16.5% | |
| Q3 2021 | +9.0% | +18.4% | +4.0% | |
| Q1 2021 | +0.0% | +0.0% | +4.9% | |
| Q4 2020 | +21.2% | +28.4% | +1.5% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro